Exvade Bioscience Enrolls First Patients in Revolutionary Glioblastoma Trial Using FDA Breakthrough Tumor Monorail Device
核心洞察
Exvade Bioscience (搜索) has begun enrolling patients in a Phase 1 clinical trial testing the FDA Breakthrough Device "Tumor Monorail (搜索)" for real-time monitoring and treatment of recurrent glioblastoma (搜索) at Duke University (搜索).
The innovative implantable catheter system guides invasive brain tumor cells away from critical regions while enabling continuous tumor sampling without repeat surgeries.
The trial combines the Tumor Monorail (搜索) with two investigational immunotherapies, D2C7-IT and 2141-V11, delivered directly to the tumor using convection-enhanced delivery.
Exvade Bioscience (搜索) has initiated enrollment in a groundbreaking Phase 1 clinical trial (NCT04547777) at Duke University (搜索)'s Preston Robert Tisch Brain Tumor Center (搜索), marking the first clinical use of the company's FDA Breakthrough Device "Tumor Monorail (搜索)" for treating recurrent glioblastoma (搜索). Early results indicate a favorable safety profile for the innovative device, which represents a paradigm shift in brain cancer (搜索) treatment by enabling real-time tumor monitoring without repeated surgeries.
Revolutionary Approach to Brain Cancer Treatment
The Tumor Monorail (搜索) represents the first-ever bio-inspired implant designed to guide invasive brain tumor cells away from critical brain regions toward a designated "safe zone" outside the brain. The surgically implanted catheter system remains in place throughout treatment, providing continuous access to tumor biology and enabling longitudinal monitoring of tumor evolution and response to therapy.
"By allowing real-time monitoring of the tumor over time, while on therapy, we will hopefully be able to more swiftly identify the degree of efficacy or the limitations of our therapies, while preventing the trauma and costs of repeated brain surgery," said Dr. Annick Desjardins, MD, FRCPC, neuro-oncologist, professor of neurosurgery and neurology at Duke University (搜索) and the study's principal investigator.
Combination Immunotherapy Protocol
The Phase 1 study enrolls adults with recurrent glioblastoma (搜索) who have undergone prior standard therapy to evaluate a dual approach combining two investigational immunotherapies with the Tumor Monorail (搜索) monitoring system. The treatment protocol involves D2C7-IT, an investigational immunotoxin designed to target and bind to both wild-type EGFR (搜索) and EGFRvIII (搜索) proteins frequently overexpressed in glioblastoma (搜索) cells, administered in combination with 2141-V11, a fully-human anti-CD40 (搜索) agonist antibody.
The therapeutic regimen begins with insertion of the Tumor Monorail (搜索) in proximity to tumor recurrence, followed by direct intracerebral administration of both D2C7-IT and 2141-V11 using convection-enhanced delivery (CED). This method bypasses the blood-brain barrier to allow high concentrations of drug to reach tumor-infiltrated regions. Patients then undergo repeated dosing of 2141-V11 subcutaneously in the cervical perilymphatic area to maintain immune response, while the Tumor Monorail enables real-time tumor evaluation through subcutaneous needle aspiration at each dosing interval.
Addressing Critical Unmet Medical Need
Glioblastoma (搜索) affects approximately 12,300 Americans annually, with an incidence of 3.2 per 100,000 population. The disease carries a devastating prognosis, with median survival from initial diagnosis of less than 21 months. Current standard of care involves maximal safe surgical resection followed by radiotherapy plus concomitant and maintenance temozolomide chemotherapy, with or without the Optune device. Critically, no standard treatment exists for tumor recurrence.
"Serial tumor sampling remains one of the most critical unmet needs - and what many consider the holy grail - in glioblastoma (搜索) therapeutic development and clinical advancement," said Nassir Mokarram, co-inventor of Tumor Monorail (搜索) and co-founder of Exvade Bioscience (搜索). "Many clinical trials today struggle to confirm whether therapies are effectively reaching the tumor, producing meaningful biological effects, or overcoming emerging resistance."
Clinical Trial Design and Eligibility
The study enrolls adults aged 18 or older with histologically confirmed recurrent glioblastoma (搜索) following prior standard therapy including surgery, radiation, and chemotherapy. The trial incorporates two key components: evaluation of Tumor Monorail (搜索) safety and feasibility for tumor monitoring, and testing of the combination immunotherapy approach targeting cancer cells with enhanced precision.
Platform Technology with Broader Applications
Exvade Bioscience (搜索) positions the Tumor Monorail (搜索) as a breakthrough platform technology that introduces a fundamentally new concept of guiding and moving tumor cells rather than relying solely on destruction. While neuro-oncology serves as the entry point, the platform is designed to expand to other hard-to-treat solid tumors and enable precision medicine through localized and targeted drug delivery. The technology has received support from the National Institutes of Health, Ian's Friends Foundation, and the Marcus Foundation.
Mokarram emphasized the potential impact: "We believe effective treatments for many glioblastoma (搜索) patients may already exist - but progress has been constrained by the lack of timely, accurate, and actionable insight into the tumor and its microenvironment. Tumor Monorail (搜索) has the potential to dramatically accelerate the pace at which new treatments are validated, optimized and personalized for patients."